Smith & Nephew SNATS (NYSE:SNN) Cut to Buy at Wall Street Zen

Posted by Francis Steltz on Aug 11th, 2026

Wall Street Zen lowered shares of Smith & Nephew SNATS (NYSE:SNN – Free Report) from a strong-buy rating to a buy rating in a research note released on Saturday morning.

SNN has been the subject of a number of other reports. Weiss Ratings cut shares of Smith & Nephew SNATS from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, June 11th. The Goldman Sachs Group reiterated a “buy” rating on shares of Smith & Nephew SNATS in a report on Monday, May 25th. Barclays cut shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, August 5th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew SNATS in a research note on Thursday, August 6th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Smith & Nephew SNATS has a consensus rating of “Hold” and an average target price of $30.93.

Check Out Our Latest Analysis on SNN

Smith & Nephew SNATS Trading Down 0.1%

Shares of SNN stock opened at $30.09 on Friday. The firm has a 50 day moving average of $30.47 and a 200-day moving average of $32.10. The company has a quick ratio of 1.11, a current ratio of 2.14 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS has a 52 week low of $28.56 and a 52 week high of $38.79.

Smith & Nephew SNATS Dividend Announcement

The firm also recently declared a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be given a $0.312 dividend. The ex-dividend date of this dividend is Friday, October 2nd. This represents a yield of 205.0%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Clearstead Trust LLC acquired a new position in shares of Smith & Nephew SNATS during the second quarter valued at about $25,000. Garner Asset Management Corp acquired a new stake in shares of Smith & Nephew SNATS in the 4th quarter worth about $27,000. Arax Advisory Partners raised its holdings in shares of Smith & Nephew SNATS by 142.6% in the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock worth $32,000 after acquiring an additional 569 shares during the last quarter. Advisors Asset Management Inc. acquired a new stake in shares of Smith & Nephew SNATS in the 4th quarter worth about $36,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in Smith & Nephew SNATS in the 3rd quarter valued at about $41,000. Institutional investors and hedge funds own 25.64% of the company’s stock.

Smith & Nephew SNATS Company Profile

(Get Free Report)

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.